Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label trial of prolonged-release dienogest/ethinyl estradiol formulations versus Velmari flexible regimen for ovulation inhibition
2016-003830-26Phase 2Completed
- Sponsor
- Exeltis
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of LPRI-421 and Velmari in contraception (4 arms), sponsored by Exeltis. Primary endpoint: Inhibition of ovulation by Hoogland score. Started Dec 2016; status: completed.
02
Drugs
LPRI-421Velmari
03
Conditions
contraception
Beyond the preview
Go deeper on 2016-003830-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003830-26.